Cizzle Biotech Partners with Moffitt Cancer Center for Early Lung Cancer Detection

Cizzle Biotechnology Holdings, a UK diagnostics company focused on early-stage lung cancer detection, has been selected by Moffitt Cancer Center to trial its CIZ1B biomarker test on patients with suspicious lung nodules. Moffitt, Florida's top cancer hospital and a designated National Cancer Institute Comprehensive Cancer Center, will use the CIZ1B biomarker assay as part of its comprehensive lung cancer screening program.

This collaboration marks the first time that Cizzle’s test will be used in a major clinical evaluation in the US, following rigorous scientific reviews and partnerships through Cizzle Bio Inc. Blood samples from US patients will be analyzed at the University of York to determine the test’s accuracy in identifying early-stage lung cancer. The study, led by Dr. Lary Robinson at Moffitt, aligns with US national guidelines and aims to provide critical new data on the sensitivity and specificity of the biomarker test.

Cizzle Bio Inc. has been building clinical partnerships across the US since signing a Memorandum of Understanding (MOU) in April 2024. The collaboration with Moffitt is seen as a significant step in advancing early lung cancer detection and bringing Cizzle’s proprietary test to the global market.

Lung cancer remains the leading cause of cancer-related deaths worldwide, with nearly 5,000 people dying daily. Current screening methods, like low-dose CT scans, often result in false positives, leading to unnecessary stress and costly follow-up procedures. Cizzle’s CIZ1B biomarker test offers a promising solution by potentially reducing false positives and helping clinicians better identify early-stage cancer, improving patient outcomes.

Executive Chairman Allan Syms emphasized that the partnership with Moffitt highlights the progress in Cizzle’s development and the expansion of its US operations, with plans to launch the test globally. Dr. Lary Robinson of Moffitt added that a reliable blood test for early lung cancer detection could revolutionize screening processes and save lives, calling the CIZ1B biomarker test a potential breakthrough.